Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology
-$2.58 today
- Market cap
- $1.02B
- Beta
- 3.32
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$8.35
Volume 0.29M
Average 0.43M
INBX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Inhibrx Biosciences, Inc.NASDAQ: INBX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.65M rose 8.3% year over year, ahead of the -79.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at -18.3% a year.
Context
- Stock-based compensation amounted to 856.8% of revenue in FY2025, down 28402.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.3% holds above the trailing-twelve-month pace of -79.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.14M USD
- Year-over-year change
- -81.0%
- 4-year CAGR
- -7.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.14M | -81.0% |
| FY2024 | 2024-12-31 | 58.52M | +135.5% |
| FY2023 | 2023-12-31 | 24.85M | +21.5% |
| FY2022 | 2022-12-31 | 20.45M | +35.9% |
| FY2021 | 2021-12-31 | 15.05M | — |
Stock-Based Compensation vs competitors
How INBX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -79.7% is the lowest of 7, against a peer median of +0.5%.
- Stock-based compensation amounts to 872.4% of revenue for INBX, versus a peer median of 179.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.79M USD | +1.8% | +32.7% | 179.5% | |
| LTM Sep 2026 | $36.81M USD | -0.7% | — | 32869.6% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $20.58M USD | +5.7% | — | 64.5% |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $15.81M USD | +199.7% | +2009.0% | — |
| LTM Mar 2026 | $13.53M USD | -11.4% | +13.5% | 737.0% | |
| LTM Mar 2026 | $11.34M USD | -79.7% | -18.3% | 872.4% | |
| LTM Mar 2026 | €7.38M EUR | -44.8% | — | 19.8% | |
| Peer median (excluding INBX) | — | +0.5% | +32.7% | 179.5% | |
Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (81.77M) | (145.23M) | (239.73M) | 1.69B | (140.06M) |
| Depreciation & Amortization | 1.2M | 1.23M | 1.19M | 2.29M | 2.48M |
| Deferred Income Tax | (9K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.05M | 20.45M | 24.85M | 58.52M | 11.14M |
| Change in Working Capital | (17.52M) | 3.16M | 15.35M | 52.05M | (7.61M) |
| Accounts Receivables | (167K) | 130K | (521K) | 381K | 243K |
| Inventory | (11.03M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.64M) | (705K) | 2.11M | 17.9M | (3.3M) |
| Other Working Capital | (1.67M) | 3.74M | 13.76M | 33.77M | (4.56M) |
| Other Non-Cash Items | 2.73M | 5.09M | 5.03M | (1.99B) | 4.25M |
| Operating Cash Flow | (80.32M) | (115.3M) | (193.31M) | (194.41M) | (129.79M) |
| Capital Expenditures | (864K) | (686K) | (4.59M) | (2.6M) | (31K) |
| Acquisitions (Net) | 55K | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (809K) | (686K) | (4.59M) | (2.6M) | (28K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 99.84M |
| Common Stock Issued | 40.2M | 129.74M | 201.96M | 71.68M | 1.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 83.77M | 128.81M | 0 | 0 | 0 |
| Financing Cash Flow | 83.77M | 258.55M | 201.96M | 71.68M | 101.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.64M | 142.56M | 4.06M | (125.33M) | (28.38M) |
| Free Cash Flow | (81.19M) | (115.99M) | (197.9M) | (197.01M) | (129.83M) |
Inhibrx Biosciences, Inc.
NASDAQ:INBX
Intrinsic Alpha fair value
Locked
Current Price
$69.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.